Companies in the San Francisco Bay Area delivered FDA-approved breakthrough treatments last year in HIV, cancer and orphan diseases. In 2013 and afterwards, biotech companies and other drug developers will face a key challenge of whether they build a collective portfolio of new, first-in-class drugs that fuel, and in several cases reignite, venture capital and Wall Street patron interest.
With that in mind, Bay Area biotech leaders are thinking about how they can persuade government policy to ensure that innovation continues to come from Northern California. The group under the leadership of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) CEO Tony Coles and members including Chiron Corp. cofounder Ed Penhoet, BayBio’s Gail Maderis and representatives of the University of California, San Francisco, Stanford University and consulting firm Deloitte are seeking to lead changes that help the region retain its competitive edge in life sciences.[article_detail_ad_1]
Coles said that the group has met only once, but plans to meet again in early this year and will unveil its plans as soon as possible.
On Thursday, the share price of NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) lost -4.70% during trading yesterday, ending at $8.72 after the company set the annual price for Gattex, its drug for short bowel syndrome, at $295,000, which is more than triple what analysts had projected.
At that price, the company has a market cap of $755.56 billion. The stock has a 52 week worst hit of $6.15 and a 52 week high of $11.22. The P/S ratio is 5.82 and P/B ratio 6.36. The beta value is 0.55. NPSP’s RSI amounts to 35.65.
Biogen Idec Inc.(NASDAQ:BIIB) was down after its ALS drug failed Phase III Trial. In other news today, the company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc).
The market value of this company is $34.98 billion. It has 5000 people in workforce, over the last 12 months has generated revenue of $5.43 billion and has earnings of $1.39billion. The firm’s operating margin is 33.37 percent and net profit margin 25.62 percent. The latest closing price of its shares moved up 1.11% from the 50-day moving average.
Galena BiopharmaInc(NASDAQ:GALE) extended rally yesterday after Piper Jaffray began coverage issuing an overweight rating and a $2.50 target price on the stock.
For Galena Biopharma Inc, a return on equity of -296.55 percent has been realized due to the financial position. Last twelve months per-share profit reached a value of -$0.54. The stock closed at $1.70, up 0.11 points or 6.92% from previous close and at a distance of -4.49% from 20-day simple moving average.
In the last trading session, Sarepta Therapeutics Inc (NASDAQ:SRPT)’s price moved 109.38% above its 200 day moving average, changing hands as low as $26.22 per share. The stock is currently trading 9.50% up its SMA 50. The worst hit in its 52 week range is $2.60 per share, with $45.00 being the 52 week best price, which compares with a latest closing price of $28.14. The Beta of this stock is 1.27.